AAVhu68 Capsid Coding Sequence for Higher Vector Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The need for improved production systems capable of generating large amounts of recombinant AAV particles for gene therapy applications is a hurdle due to the limitations of existing AAVhu68 capsid coding sequences.
Innovation Solution
Novel AAVhu68 capsid coding sequences, such as AAVhu68M191, are developed to enhance the yield of recombinant AAV particles by at least 20-30% compared to the native AAVhu68 coding sequences, utilizing plasmids and host cells like HEK293, Huh-7, and Vero cells, with adenovirus or herpes simplex virus helper functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If native AAVhu68 coding sequences are used for production, then the production system is simpler, but the yield of recombinant AAV particles is insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the AAVhu68 capsid coding sequence to create AAVhu68M191, which contains specific mutations (including position 191) that enhance production yield. This involves changing the nucleotide sequence parameters while maintaining the functional integrity of the capsid protein, thereby resolving the contradiction between yield improvement and sequence complexity.
2Quantity of substance
If larger amounts of recombinant AAV particles are produced, then gene therapy applications are better supported, but the production system becomes more complex
Solution Approach 1:
The patent modifies the capsid coding sequence parameters to create AAVhu68M191 with enhanced production characteristics. This parameter change enables higher particle yields without requiring fundamental changes to the production system architecture, thus increasing quantity while controlling complexity.
3Reliability
If AAVhu68M191 coding sequence is used, then packaging efficiency is maintained, but the coding sequence differs from native AAVhu68
Solution Approach 1:
The patent introduces specific parameter changes at key positions in the AAVhu68 sequence (including position 191) to create AAVhu68M191. These targeted changes maintain the essential packaging function and capsid assembly while introducing modifications that improve production yield, thus preserving reliability while accepting controlled compositional variation.
Data Source
AI summary
Provided herein are engineered nucleic acid sequences encoding AAVhu68 which provide improved yields of packaged AAVhu68 viral particles. Also provided is a packaging host cell comprising the engineered nucleotide sequence and methods of using same to product recombinant AAVhu68 vectors useful for gene delivery. Further provided are production cell supernatants comprising improved yields of recombinant AAV vectors having AAVhu68 capsids produced using the nucleotide sequences provided herein.